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Abstract
Background: Several small receptor tyrosine kinase inhibitors (RTKI) have entered clinical cancer
trials alone and in combination with radiotherapy or chemotherapy. The inhibitory spectrum of
these compounds is often not restricted to a single target. For example Imatinib/Gleevec (primarily
a bcr/abl kinase inhibitor) or SU11248 (mainly a VEGFR inhibitor) are also potent inhibitors of
PDGFR and other kinases. We showed previously that PDGF signaling inhibition attenuates
radiation-induced lung fibrosis in a mouse model. Here we investigate effects of SU9518, a PDGFR
inhibitor combined with ionizing radiation in human primary fibroblasts and endothelial cells in vitro,
with a view on utilizing RTKI for antifibrotic therapy.
Methods: Protein levels of PDGFR-α/-β and phosphorylated PDGFR in fibroblasts were analyzed
using western and immunocytochemistry assays. Functional proliferation and clonogenic assays
were performed (i) to assess PDGFR-mediated survival and proliferation in fibroblasts and
endothelial cells after SU9518 (small molecule inhibitor of PDGF receptor tyrosine kinase); (ii) to
test the potency und selectivity of the PDGF RTK inhibitor after stimulation with PDGF isoforms
(-AB, -AA, -BB) and VEGF+bFGF. In order to simulate in vivo conditions and to understand the role
of radiation-induced paracrine PDGF secretion, co-culture models consisting of fibroblasts and
endothelial cells were employed.
Results: In fibroblasts, radiation markedly activated PDGF signaling as detected by enhanced
PDGFR phosphorylation which was potently inhibited by SU9518. In fibroblast clonogenic assay,
SU9518 reduced PDGF stimulated fibroblast survival by 57%. Likewise, SU9518 potently inhibited
fibroblast and endothelial cell proliferation. In the co-culture model, radiation of endothelial cells
and fibroblast cells substantially stimulated proliferation of non irradiated fibroblasts and vice versa.
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Importantly, the RTK inhibitor significantly inhibited this paracrine radiation-induced fibroblast and
endothelial cell activation.
Conclusion: Radiation-induced autocrine and paracrine PDGF signaling plays an important role in
fibroblast and endothelial cell proliferation. SU9518, a PDGFR tyrosine kinase inhibitor, reduces
radiation-induced fibroblast and endothelial cell activation. This may explain therapeutic anticancer
effects of Imatinib/Gleevec, and at the same time it could open a way of attenuating radiation-
induced fibrosis.
Background
The development of fibrosis is a frequent side effect that
may be caused by a variety of inductors. Fibrosis especially
hampers cancer treatment such as radiotherapy and chem-
otherapy, thus severely limiting cancer therapy success.
Furthermore, the development of fibrosis may reflect the
integrative and interdependent roles of various cell com-
pounds in tumor biology calling into question reduction-
ist approaches focus on individual tumor cell
compartment. Fibrosis occurs in many organs. Lung fibro-
sis for example may be caused by radiotherapy, chemo-
therapeutic drugs (such as bleomycin), amiodaron or,
chemical substances (like asbestos fibers and silica parti-
cles, etc [1]). With the progression of the disease patients
develop severe clinical symptoms limiting oxygenation of
the blood and patients' survival. Treatment of fibrosis
remains elusive given that the exact mediators and mech-
anisms involved in fibrogenesis are unknown [2,3].
Fibrosis is characterized by the excessive proliferation of
mesenchymal cells (fibroblasts, myofibroblasts, and
smooth muscle cells) and the subsequent deposition of
extracellular matrix proteins [2]. Fibroblasts exhibit
increased chemotaxis, proliferation, and extracellular
matrix production in fibrotic lung and skin [2,4].
Cytokines such as platelet-derived growth factor (PDGF),
transforming growth factor (TGF)-α and -β, interleukin
(IL)-1α and -β, and basic fibroblast growth factor (bFGF)
have emerged as major stimulators of the fibroprolifera-
tive process induced by diverse stimuli such as ionizing
radiation [5-7].
Here we focus on PDGF which has been implicated in a
wide variety of pathological processes, including pulmo-
nary fibrosis and skin fibrosis [8-10]. PDGF is a disulfide-
linked dimer of two related polypeptide chains, desig-
nated A, B, C and D, which are assembled as heterodimers
(PDGF-AB) or homodimers (PDGF-AA, PDGF-BB, PDGF-
CC and PDGF-DD) [11]. PDGF exerts its biological activ-
ity by binding to structurally similar PDGF receptors
(PDGFR-α and -β). It induces receptor dimerization and
autophosphorylation of the receptor tyrosine kinase
(RTK). Activated RTK phosphorylates numerous signaling
molecules that initiate the intracellular signaling cascades
leading to cell proliferation and survival [12]. These phos-
phorylation-dependent interactions are essential for the
activation of intracellular signaling pathways that can lead
to tissue fibrosis. It seems reasonable to assume that
blocking phosphorylation of PDGFR could be a way of
preventing biological effects of this cytokine and thus
fibrogenesis.
Recently, we have demonstrated this concept in vivo in a
radiation-induced lung fibrosis model in mice by showing
that inhibition of PDGF signaling functionally attenuates
pulmonary fibrosis [13]. Here we analyze the underlying
mechanistic cell effects in vitro with respect to the cellular
pathway of RTK inhibition and to radiation for the PDGF/
PDGFR system in human primary fibroblasts and
endothelial cells.
Materials and methods
Endothelial and fibroblast cell cultures and reagents
Primary isolated human dermal microvascular vein
endothelial cells (HDMVEC, Promocell, Heidelberg, Ger-
many) and primary isolated human fibroblasts (Promo-
cell, Heidelberg, Germany) were cultured up to passage 6.
Cells were maintained in culture at 37°C with 5% CO2
and 95% humidity in serum reduced (5% fetus calf
serum) modified promocell media (MPM) supplemented
with 2 ng/ml vascular endothelial growth factor (VEGF)
and 4 ng/ml basic fibroblast growth factor (bFGF). This
combination of VEGF and bFGF optimized growth kinet-
ics [14]. Human recombinant VEGF and bFGF proteins
were purchased from Promocell.
Western blotting
Primary human lung fibroblasts were grown in modified
media supplemented with 5% fetus calf serum containing
2 ng/ml VEGF and 4 ng/ml bFGF in 125 cm2 flasks. Cells
were then treated either with 10 Gy or 5 µM SU9518
exclusively or in combination with both (1 hour SU9518
incubation prior to radiation). 1/2 hour after radiation
fibroblasts were washed twice with ice-cold PBS, lysed
with 250 µl ice-cold cell lysis buffer (1 M Tris, 5 M NaCl,
1 mM EDTA, 1 mM EGTA, pH 8.01). Lysates were kept on
ice, and centrifuged at 4°C for 10 minutes at 13000 rpm.
Supernatant was collected for western blotting assay as
described [15]. Proteins were transferred from a polyacry-
lamide gel to a nitrocellulose membrane with a Mini-BMC Cancer 2006, 6:79 http://www.biomedcentral.com/1471-2407/6/79
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Trans-Blotter (100 V for 90 minutes) in transfer buffer.
After transfer, non-specific binding sites were blocked for
1 hour with 5% non-fat milk powder in TBST buffer (15
mM NaCl, 1 mM TRIS-HCl, 0.1% Tween 20, pH 8.0) at
room temperature. Each primary antibody (anti-PDGFR-
α, anti-PDGFR-β and anti-phosphorylated PDGFR-β, Cell
Signaling Technology, Inc. Germany) was diluted in
blocking buffer and incubated with the membrane over-
night at 4°C. After washing in TBST, the nitrocellulose
membrane was incubated with horseradish peroxidase-
conjugated antibody in blocking buffer at room tempera-
ture for 60 minutes. Antibody binding was determined
using the enhanced chemiluminescence detection system
according to the manufacturer's instructions. Exposures
were recorded on hyperfilms for 10 seconds to 3 minutes.
Immunocytochemistry
Fibroblasts were cultured as in the western blotting assay.
After trypsinization of fibroblasts in flasks, 20 µl cell sus-
pensions (3 × 104 cells/ml) were seeded on slips and incu-
bated for 24 hour at 37°C with 5% CO2  and 95%
humidity. After treatments with radiation (10 Gy),
SU9518 (5 µM) or SU9518 + radiation (1 hour incuba-
tion with SU9518 prior radiation), fibroblasts were incu-
bated 1/2, 6, 12 or 24 hours in MPM. After stimulation
fibroblasts were washed with phosphate-buffered saline
(PBS) and fixed with methanol and acetone 5 minutes at
-20°C respectively. After washing with PBS, fibroblasts
were permeabilized for 30 minutes with PBS containing
1% tween-20 (Merck, Darmstadt, Germany), and blocked
for 30 minutes with PBS blocking buffer (containing 5%
FBS with 1% tween-20). The cells were incubated for 12
hours at 18–20°C in blocking buffer with 3 primary anti-
bodies: anti-PDGFR-α, anti-PDGFR-β and anti-phosphor-
ylated PDGFR-β (Cell Signaling Technology, Inc.
Germany). After washing with PBS, the cells were incu-
bated for 1 hour at room temperature with 1:250 second-
ary antibodies, goat anti-mouse IgG (Alexa Fluor 488) or
goat anti-rabbit IgG (Alexa Fluor 488), and mixed 1:200
with bromphenolblue (Sigma, St. Louis, USA) solution
for cell nucleus staining. After further washing slides were
mounted in Citifluor mounting medium and were exam-
ined with a fluorescence microscope (400X, software
Openlab 3.1.4, Leica, DMIRB).
Clonogenic survival assay
To investigate the effects of SU9518 on clonogenic sur-
vival of fibroblast and endothelial cells, cells were plated
with increasing numbers (102 to 5 × 104) in 25 cm2 flasks.
Cells were incubated with 0–10 µM SU9518 in presence
of 10 ng/ml PDGF-AB. Flasks were returned to the incuba-
tor for 14–17 days, after which they were stained with
crystal violet (Sigma, Germany). Colonies were counted
and the surviving percentage was determined for clono-
genic survival after correcting for plating efficiency.
Proliferation assay
Cells were harvested by trypsinization at 37°C and neu-
tralized with trypsin-neutralizing solution. A suspension
of 50000 cells in MPM/DMEM was added to 25 cm2 flasks
(Becton Dickinson, Heidelberg, Germany). Cells were
incubated with SU9518 for 1 hour in cytokine-free
medium at standard conditions and incubated for
another 72 hours in final mediums (either with 10 ng/ml
PDGF-AB, or with 2 ng/ml VEGF + 4 ng/ml bFGF). Cells
were then dispersed in trypsin, resuspended, and counted
in a coulter counter.
In fibroblasts, PDGF-isoform dependent proliferation
assays were performed as follows: Fibroblasts were cul-
tured and plated as in the clonogenic assay. Cells were
incubated for 72 hours either with PDGF (-AA, -AB, -BB,
each isoform in 2 and 10 ng/ml) alone, or with additional
administration of 5 µM SU9518. Cells were then dis-
persed in trypsin, resuspended, and counted in a coulter
counter.
Co-culture model
A proliferation assay in a co-culture model was used to
assess the proliferation ability of cells in the upper com-
partments after irradiation of cells in the lower compart-
ments with or without SU9518 treatment. Human dermal
microvascular endothelial cells (HDMVECs) were grown
in 24 well plates. At confluence, the media were changed.
Cells were irradiated with 10 Gy using a 6 MeV x-rays lin-
ear accelerator at a dose rate of 118 cGy/min. Transwell
inserts of upper compartments with a 0.6 µm pore size
were plated with 20,000 cells. In SU9518 treated groups
and SU9518 + radiation groups, cells in upper compart-
ments were preincubated with 5 µM SU9518 for 1 hour.
After selective irradiation of cells in lower compartments,
transwells of upper compartments containing cells were
transferred into the 24 well plates, incubated for 72 hours
at standard conditions, then dispersed in trypsin, resus-
pended and counted. Three conditions were analyzed: (A)
irradiated fibroblast cells in the lower compartment, as
the chemotactic "agent" after radiation, and (non irradi-
ated) fibroblasts in the upper compartment; (B) irradiated
HDMVEC in the lower compartment and fibroblasts in
the upper compartment; (C) irradiated fibroblasts in the
lower compartment and non irradiated HDMVEC in the
upper compartment.
Statistical analysis
Statistical analyses were performed with a statistical anal-
ysis software system (Statistica 6.0). Student's t test was
used to compare means. For multiple comparisons
ANOVA was used with Fisher's least-significant difference
method. P-values less than 0.05 were considered statisti-
cally significant.BMC Cancer 2006, 6:79 http://www.biomedcentral.com/1471-2407/6/79
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(a) Western-blotting analysis of PDGFR-α/-β and phosphorylated PDGFR-β (p-PDGFR-β) Figure 1
(a) Western-blotting analysis of PDGFR-α/-β and phosphorylated PDGFR-β (p-PDGFR-β). Human dermal fibroblast cells were 
treated with or without 5 µM SU9518 for 1 hour before 10 Gy irradiation. Whole cell lysates of fibroblasts were collected for 
protein content and separated by SDS-PAGE and transferred to nitrocellulose. The amount of PDGFR and phosphorylated 
PDGFR was visualized with anti-PDGFR-α, anti-PDGFR-β or anti-phosphorylated PDGFR-β antibodies, respectively. Radiation-
induced PDGFR phosphorylation was markedly inhibited by SU9518. (b) Immunocytochemistry of human primary dermal 
fibroblast cells. Fibroblasts were analyzed as untreated (control), after SU9518 (5 µM), irradiation (10Gy) or combined SU9518 
and radiation treatment. The cells were incubated 6 hours post radiation and stained with the polyclonal rabbit anti-PDGFR-β/
anti-p-PDGFR-β antibody followed by incubation with Alexa Fluor 488 goat anti-rabbit secondary antibody. For nuclear locali-
zation the cells were counterstained with propidium jodide (red color). Immunofluorescence staining for PDGFR-β/p-PDGFR-
β was indicated by green fluorescence. Irradiation-induced phosphorylation of PDGFR-β and that was substantially inhibited by 
SU9518. Scale bar presents 25 µm.BMC Cancer 2006, 6:79 http://www.biomedcentral.com/1471-2407/6/79
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Results
PDGFR protein regulation in fibroblasts
To investigate the impact of radiation to PDGFR in fibrob-
lasts and the effect of SU9518 on phosphorylation of
PDGF RTK in fibroblasts after radiation, human dermal
fibroblast cells were pre-treated with 5 µM SU9518 one
hour before 10 Gy irradiation and incubated for 30 min-
utes (Figure 1a). PDGFR levels as well as PDGFR phos-
phorylation were determined by western-blotting using
primary antibodies specific to PDGFR-α, PDGFR-β or
phosphorylated PDGFR-β (p-PDGFR-β), respectively.
Irradiation stimulated overexpression of both PDGFR-α
and -β in fibroblasts, while expression of PDGFR-β was
more upregulated than PDGFR-α. Moreover, irradiation
resulted in significantly increased PDGFR-β phosphoryla-
tion while SU9518 treatment particularly inhibited phos-
phorylation of PDGFR-β.
Immunocytochemistry
To investigate radiation-induced PDGF signaling in
fibroblasts in the presence or absence of SU9518, immu-
nocytochemistry analyses were performed at various time
points (1/2, 1, 6 hours) after irradiation. Irradiation
resulted in enhanced phosphorylation of PDGFR-β (p-
PDGFR-β) in fibroblasts. Representative microscopic pho-
tos of fibroblasts with PDGFR-β or p-PDGFR-β staining
are presented at time points 1/2 and 6 hours after radia-
tion, respectively (Fig. 2b). Importantly, the autophos-
phorylation of PDGFR-β was markedly inhibited by 5 µM
SU9518, consistent with the results in western-blotting
assays.
Fibroblasts clonogenic survival
In the clonogenic survival assay, stimulating effects of
PDGF (-AB isoform, 10 ng/ml) on fibroblast cells were
examined in the absence or presence of SU9518 with
increasing concentrations (Figure 2a). Inhibition of PDGF
signaling by SU9518 reduced the clonogenic survival frac-
tion of fibroblasts. The surviving fraction of fibroblasts
was reduced by 10 µM SU9518 to 0.23 fold (Figure 3),
suggesting that PDGF played a role for the clonogenic sur-
vival of fibroblasts which in turn would explain why the
small molecular RTK inhibitor SU9518 inhibits fibroblast
clonogenic survival.
Endothelial cell clonogenic survival
In the clonogenic survival assay (Figure 3a), the inhibitory
effects of SU9518 on human dermal microvascular
endothelial cells (HDMVECs) were examined in the pres-
ence of PDGF (-AB isoform, 10 ng/ml). Inhibition of
PDGF signaling with SU9518 reduced the survival frac-
tion of endothelial cells, which underscored the impor-
tance of the PDGF pathway for the survival of endothelial
cells. For example, using 5 µM SU9518, surviving fraction
of endothelial cells decreased to 42% and further to 22%
at 10 µM SU9518. Thus the PDGF-mediated clonogenic
survival of endothelial cells was significantly inhibited by
the administration of SU9518 in a dose dependent man-
ner.
Endothelial cell proliferation
To further evaluate the specificity of SU9518, its ability to
inhibit PDGF-stimulated endothelial proliferation was
(a) Clonogenic survival assay of dermal fibroblasts Figure 2
(a) Clonogenic survival assay of dermal fibroblasts. Fibroblast 
cells (102 to 5 × 104) were incubated with 0–10 µM SU9518 
in presence of 10 ng/ml PDGF-AB. Cultures were returned 
to the incubator for 14–17 days, after which they were 
stained with crystal violet (Sigma, Germany). Colonies were 
counted and the surviving percentage was determined for 
clonogenic survival after correcting for plating efficiency. Bars 
are means of 5 experiments ± SD. (b) Clonogenic survival 
assay of human dermal microvascular endothelial cells 
(HDMVECs). Endothelial cells were treated with 0–10 µM 
SU9518 in the presence of 10 ng/ml PDGF-AB in the media. 
Surviving fraction was calculated based on the number of col-
onies counted after 14–17 days. Bars are means of 5 experi-
ments ± SD.BMC Cancer 2006, 6:79 http://www.biomedcentral.com/1471-2407/6/79
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measured and compared with its inhibitory potency to
endothelial proliferation stimulated by VEGF and bFGF.
We found that SU9518 inhibited 10 ng/ml PDGF-induced
endothelial proliferation with an IC50 of approximately
0.9  µM. PDGF-induced proliferation was effectively
blocked by SU9518, whereas endothelial proliferation
stimulated by VEGF and bFGF was inhibited to a much
lesser degree by SU9518 (Figure 2b). For example, the cell
number reduction by 1 µM SU9518 was 52% after PDGF
stimulation versus 13% after stimulation by VEGF and
bFGF.
PDGF-isoforms dependent fibroblasts proliferation
Several PDGF-isoforms are found to stimulate different
PDGFR subtypes. To further assess the effects of SU9518
we investigated the PDGF-isoforms dependent inhibition
of fibroblast proliferation at 2 ng/ml or 10 ng/ml concen-
trations of various PDGF-isoforms. We found that
SU9518 significantly inhibited fibroblast proliferation
induced by all three PDGF-isoforms at a concentration of
5 µM (Figure 4). The inhibitory potency of SU9518 to
PDGF-AB and -BB appeared to be slightly greater than -
AA, while that to PDGF-AB was the most pronounced
among the three isoforms.
Radiation-induced interactions between fibroblasts and 
endothelial cells
To investigate the interactions between fibroblasts and
endothelial cells a co-culture model was used. Irradiation
(10 Gy) of human dermal microvascular endothelial cells
(HDMVECs) stimulated paracrine fibroblast proliferation
(2.1 fold). Likewise, irradiation of fibroblast cells also
stimulated fibroblast cells and endothelial cells in the non
irradiated upper compartment up to 1.5 fold (Figure 5).
Importantly, the paracrine fibroblast stimulation by either
fibroblast or endothelial cells was markedly reduced with
the administration of SU9518 by approximately 50% (P <
0.001). Thus SU9518 could significantly inhibit the acti-
vation of radiation-induced direct and indirect fibroblast
activation.
Discussion
In the context of fibrosis development in conventional
cancer therapy, including radio- and chemotherapy, we
studied here the effects of SU9518, a receptor tyrosine
kinase inhibitor of PDGF signaling on human primary
dermal fibroblasts and endothelial cells. We had previ-
ously shown that using this class of molecular targeted
compounds – including SU9518 and Imatinib (Gleevec)
as well as SU11657 (similar to SU11248, a compound
currently in several clinical phase I and II anticancer trials)
– can attenuate ionizing radiation-induced lung fibrosis in
vivo if it is given either prior to or after radiation insult
[13]. Here we investigate in vitro whether primary human
endothelial and fibroblast cells are an important primary
target of the RTK inhibitor in the context of PDGF signal-
ing. We found that, in vitro, irradiation of fibroblasts and
endothelium induced autocrine and paracrine PDGF
expression. Functionally, the isolated irradiation of pri-
mary human endothelial cells stimulated proliferation in
human fibroblasts in a co-culture model. Thus irradiation
has effects which can be described as an indirect promo-
tion of fibroblast survival and proliferation. Importantly,
RTK inhibitors could effectively attenuate this paracrine
radiation-induced activation by blocking autophosphor-
ylation of PDGFR and by downregulation of PDGFR
expression. Since fibroblasts are most likely key players in
radiotherapy related fibrosis, and given the close correla-
tion between PDGF signaling and fibroblasts activity (e.g.
survival and proliferation), along with results in vivo [13]
we conclude that fibroblasts may as well be a target of RTK
inhibitors in the process of attenuating radiation-induced
fibrogenesis in vivo.
This conclusion is in agreement with earlier reports show-
ing that PDGF is a potent mitogen and chemoattractant
for mesenchymal cells and also a chemoattractant for neu-
trophils and monocytes [16-18]. Similarly, several studies
had reported that PDGF isoforms and their receptors were
upregulated during pathologic fibroproliferative diseases
in humans and in murine models by different types of
impairment (e.g. radiation- [19,20]/bleomycin- [11]
induced fibrosis, idiopathic pulmonary fibrosis [21]) vin-
Proliferation assay of HDMVECs Figure 3
Proliferation assay of HDMVECs. Endothelial cells were 
plated in collagen I-coated flask and stimulated with 10 ng/ml 
PDGF (black line) or 2 ng/ml VEGF + 4 ng/ml bFGF (red line) 
in the absence or presence of SU9518 with increasing con-
centration (0.1, 0.5, 1, 2 and 5 µM). 72 hours later cells were 
counted and normalized to respective controls without 
SU9518.BMC Cancer 2006, 6:79 http://www.biomedcentral.com/1471-2407/6/79
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dicating the importance of the PDGF/PDGFR system in
proliferative diseases.
PDGFR-β has been suggested to be predominantly
expressed in fibroblasts [12] in agreement with our data
presented here. In addition, we found that PDGFR-β was
more upregulated after radiation in fibroblasts compared
with PDGFR-α in both western blotting and immunocyto-
chemistry assays. Others had shown that fibroblasts iso-
lated from rat lungs over expressed PDGFR-β with higher
chemotactic response to PDGF-BB in vivo [20]. Although
the ultimate mechanism of PDGFR overexpression
remains unclear, we found ionizing radiation can upregu-
late PDGFR in fibroblasts. More importantly, for the ulti-
mate goal of treating or preventing fibrosis in patients, we
found that SU9518 attenuated the radiation-induced
upregulation of PDGFR.
The best characterized mechanisms by which PDGF
down-streaming signaling mediates cellular responses
involve the activation of the ras/MAPK pathway, which
can functionally increase cellular proliferation, and the
PI3k/Akt pathway, which promotes cell survival in general
tumor biology [22]. PDGF has also been shown to stimu-
late mitogenicity and chemotaxis of fibroblasts and
smooth muscle cells [12]. In our fibroblast clonogenic
and proliferation assays, inhibition of PDGF signaling by
SU9518 significantly reduced the clonogenic survival frac-
tion and the proliferation of fibroblasts, thus supporting
the important role of PDGF signaling for fibroblasts sur-
vival. Moreover, PDGF has been shown to stimulate the
production of several matrix molecules, such as collagen,
fibronectin, and proteoglycan [23-25]. The resulting close
correlation between PDGF/PDGFR and fibroblasts may
explain the inhibitory effect of SU9518 to radiation-
induced fibrosis [13].
To further evaluate the specificity of SU9518, its ability to
inhibit cell proliferation stimulated by PDGF (-AB iso-
form) or combined VEGF and bFGF was measured,
because these growth factors have been shown to induce
similar signaling pathways, changes in gene expression,
and cellular responses in mesenchymal cells [26].
Unresolved issues in fibrosis research inlclude the relative
contribution of different cell types to the fibrotic develop-
ment and the usefulness of acute anti-inflammatory drugs
such as corticosteroids. A Cochrane review of corticoster-
oids in idiopathic lung fibrosis found no evidence that
steroid treatment was of any benefit, in spite of repression
of early inflammation [27]. Savikko et al demonstrated
that cyclosporin A treatment cannot inhibit the expression
of PDGF ligands and receptors, although it ameliorated
the extent of inflammation [28]. This suggests the involve-
ment of other cells besides acute inflammatory cells in the
development of fibrosis. In vivo in lungs, the radiation-
induced fibroproliferative process occurs within the
microenvironment of the distal gas exchange units con-
sisting of fibroblasts, epithelial cells [29,30] and endothe-
lial cells [31]. In agreement with our co-culture results,
endothelial cells are described as potential sources of
PDGF after radiation [6]. Epithelial cells do not express
PDGF and PDGFR under physiological conditions. But
expression of c-sis mRNA in epithelial cells has been
reported in certain pathologic fibrotic states, such as in
patients with idiopathic lung fibrosis [21].
SU9518 exerts its inhibitory effect by ATP-competitive
inhibition of the catalytic activity of the tyrosine kinase
after PDGFR activation [32]. Under normal conditions
PDGF-AA induces α/α receptor dimers, PDGF-AB induces
α/α and α/β receptor dimers and PDGF-BB induces all
three receptor dimer combinations. Since SU9518 inhib-
ited fibroblast proliferation activated by all three iso-
forms, it is conceivable that SU9518 can inhibit both
PDGFR-α and -β.
Despite many investigations, the relative roles of most
cytokines/growth factors in fibroproliferative diseases are
not completely defined. For some of the putative key play-
ers such as TGF-β, IL-1, TNF-α and thrombin it has been
reported that they may exert their profibrotic activities
through a PDGF-dependent pattern [33-36]. One should
keep in mind however that in the case of ionizing radia-
PDGF-isoform dependent fibroblast proliferation assay Figure 4
PDGF-isoform dependent fibroblast proliferation assay. 
Fibroblasts were stimulated by PDGF-isoforms (-AA, -BB and 
-AB) at 2 ng/ml or 10 ng/ml for 72 hours after 1 hour pre-
treatment with or without SU9518. SU9518 inhibited all 
three isoforms stimulated proliferation of fibroblasts (p < 
0.05). The extent of inhibition was greater for PDGF-AB and 
-BB. Bars are means of 5 experiments ± SD.BMC Cancer 2006, 6:79 http://www.biomedcentral.com/1471-2407/6/79
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tion the signaling cascades in cells are complex and the
resulting regulations may well be described as a network
of signaling [36-40]. Nevertheless, PDGF may be an
important node in this network and thus a key cytokine
responsible for the fibrotic development, suggesting that
perturbation of the PDGF/PDGFR system could provide
an effective means of inhibiting fibrosis.
Conclusion
Radiation-induced autocrine and paracrine PDGF signal-
ing plays an important role in fibroblast and endothelial
cell activation and proliferation. PDGFR tyrosine kinase
inhibition reduces radiation-induced fibroblast activa-
tion. This data supports the notion that SU9518 might
exert its antifibrotic activity in vivo via attenuation of
PDGF signaling. These results warrant further studies
investigating how tyrosine kinase inhibitors with anti-
PDGF property may attenuate cancer therapy related
fibrosis in addition to their primary antitumoral activity.
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